预约演示
更新于：2026-09-09
Buspirone Hydrochloride
盐酸丁螺环酮
更新于：2026-09-09
概要
基本信息
简介BuSpar®（盐酸丁螺环酮）是一种抗焦虑药，与苯二氮平、巴比妥类或其他镇静/抗焦虑药物在化学结构或药理作用上均不相同。它的作用机制尚不完全清楚，但据信涉及血清素（5-HT1A）受体。BuSpar用于治疗焦虑症或缓解焦虑症状的短期症状（与日常生活中的压力相关的焦虑或紧张通常不需要治疗），其不会引起抗惊厥或肌肉松弛作用，并且不会导致明显的镇静作用。BuSpar于1986年9月29日首次获得FDA批准上市，上市厂家为Bristol Myers Squibb Co.。 |
药物类型 小分子化药 |
别名 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione、Buspirone、Buspirone hydrochloride (USP) + [16] |
作用方式 激动剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂) |
非在研适应症- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-09-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H32ClN5O2 |
InChIKeyRICLFGYGYQXUFH-UHFFFAOYSA-N |
CAS号33386-08-2 |
关联
114
项与 盐酸丁螺环酮 相关的临床试验NCT07439042
A Randomized Controlled Trial of Buspirone for Anxiety in Autistic Youth
CTR20262917
盐酸丁螺环酮片空腹生物等效性试验
IRCT20260428069196N1
Investigating the effect of lorazepam and buspirone as a treatment along with risperidone in the treatment of symptoms in patients with schizophrenia: a double-blind, randomized, placebo-controlled clinical trial
100 项与 盐酸丁螺环酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸丁螺环酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸丁螺环酮 相关的专利（医药）
登录后查看更多信息
3,468
项与 盐酸丁螺环酮 相关的文献（医药）2026-09-01MOLECULAR PSYCHIATRY
Sterol pathway disruption in pregnancy: a link to autism
Article
作者: Peeples, Eric S ; Mirnics, Karoly ; Reisher, Elizabeth ; Dai, Ran ; Korade, Zeljka ; Anzalone, A Jerrod
Cholesterol is a vital molecule, especially during embryonic development. Disruption of the cholesterol biosynthetic pathway can arise from pathogenic genetic variants or exposure to prescription medications. We investigated the relationship between fifteen sterol biosynthesis inhibiting medications (SBIM) prescribed during pregnancy and the incidence of autism spectrum disorders (ASD) in the resulting offspring. Our study of the Epic Cosmos database queried linked child and maternal health records for births between 2014 and 2023 with follow-up to December 2025. The study included 6,135,213 children with linked maternal health records. We evaluated the incidence of ASD associated with maternal prescription of aripiprazole, atorvastatin, bupropion, buspirone, fluoxetine, haloperidol, metoprolol, nebivolol, pravastatin, propranolol, rosuvastatin, sertraline, simvastatin, and/or trazodone during pregnancy using Cox proportional hazard modeling. We found that exposure to at least one SBIM during pregnancy was associated with a 1.47-fold (95% CI 1.45-1.49) increased risk of an ASD after adjusting for potential confounders. For each additional SBIM co-prescribed, there was a 1.33 (95% CI 1.32-1.34) times increased risk of ASD, reaching 2.33-fold risk when 4 or more SBIMs were prescribed simultaneously. In the ten years of our cohort, we identified 234,971 (3.8%) children with an ASD diagnosis. Of the children with an ASD diagnosis, 35,152 (15.0%) of the mothers were prescribed at least one SBIM during pregnancy. Notably, in our dataset, utilization of SBIM medications by pregnant women increased from 4.6% in 2014 to16.8% in 2023. In conclusion, SBIMs may be potentially harmful to the developing fetus. Given that these drugs account for over 400 million prescriptions annually in the U.S. we recommend these findings be considered before prescribing SBIM medications during pregnancy.
2026-08-09Journal of Drug Targeting
Buspirone hydrochloride: a potential regulator of PD-L1 for enhanced antitumor activity in melanoma-bearing mice
Article
作者: Zhang, Chifei ; Yang, Zishan ; Tian, Zhongwei ; Ji, Xingchan ; Jiang, Hanyu ; Shao, Mingguang ; Lei, Mengyu ; Cheng, Xiaofei ; Jia, Huijie ; Zhang, Sheping ; Mo, Mingyu ; Geng, Jiaxin ; Wang, Kangle ; Zhao, Tiesuo ; Ji, Yinghua ; Guo, Sheng ; Wei, Tian ; Zhang, Yongxi
PD-1/PD-L1 blockade therapy shows good efficacy in melanoma treatment. Yet, most patients still exhibit poor responses. Exploring more effective drugs remains worthwhile. In contrast to developing new drugs which entails a lengthy process, high costs and uncertainties, repurposing old drugs is regarded as a promising and safe method, attracting greater attention. In this study, we evaluated the anti-melanoma effect of buspirone hydrochloride, a novel anti-anxiety drug. The results demonstrated that buspirone hydrochloride effectively restrained cell proliferation and migration and decreased the expression of related proteins p-STAT3, cyclin D1 and MMP2. Significantly, we discovered that buspirone hydrochloride efficiently enhanced the degradation of PD-L1. Further investigations in a melanoma-bearing mouse model showed that buspirone hydrochloride delayed the growth of tumours in tumour-bearing mice, increased apoptosis of tumour cells and inhibited cell proliferation. We found that buspirone hydrochloride treatment increased the ratio of T lymphocytes in the spleen of mice and the infiltration of T lymphocytes in tumour tissues. These findings suggest that buspirone hydrochloride not only plays an anti-melanoma role by directly inhibiting cell proliferation and promoting apoptosis but also enhances the anti-tumour immune response by suppressing PD-L1 expression, thus providing a new alternative for the development of melanoma treatment drugs.
2026-08-01BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Dose effect of buspirone combined with clozapine on cognitive function in patients with schizophrenia
Article
作者: Xu, Hui ; Zhu, Wenli ; Xia, Yuan ; Zhang, Jun ; Song, Chuanfu
Aim:
This study aimed to evaluate the augmentation effects of different doses of buspirone on psychiatric symptoms and cognitive function in patients with schizophrenia.
Methods:
A prospective study design was employed, enrolling 46 patients with schizophrenia treated at the Fourth People's Hospital of Wuhu. Patients were randomly assigned to three groups: a control group, experimental group 1 (5 mg of buspirone) or experimental group 2 (10 mg of buspirone). The control group received clozapine monotherapy, whereas the experimental groups received adjunctive buspirone at different doses alongside clozapine. The Positive and Negative Syndrome Scale (PANSS) and the Chinese version of the Repeatable Battery for the Assessment of Neuropsychological Status were used to assess psychiatric symptoms and cognitive function. A linear mixed‐effects model was employed for statistical analysis.
Results:
After 4 weeks of treatment, both experimental groups showed greater reductions in total PANSS scores than the control group (d = 0.68 and 0.82, respectively), with improvements in positive and negative symptoms being particularly pronounced in experimental group 2 (d = 0.68 and 0.85, respectively). By week 8, general symptoms had improved significantly in both experimental groups. < u > A significant group × time interaction was observed (partial η
2
= 0.15), indicating that experimental group 2 exhibited more rapid improvement than experimental group 1. With respect to cognitive function, the experimental groups demonstrated significant improvements in immediate memory (d > 0.5) and visuospatial/constructional abilities (d > 0.45) at week 8, with additional improvements in language abilities (d > 0.5) by week 12.
Conclusions:
Buspirone is effective in alleviating psychiatric symptoms and cognitive deficits in patients with schizophrenia, thereby enhancing clinical outcomes.
100 项与 盐酸丁螺环酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 1986-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 卵巢功能不全 | 临床前 | 埃及 | 2025-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 81 | 齋艱繭窪遞廠蓋選糧簾(襯醖繭網遞鹹膚鏇顧壓) = 窪築簾窪築繭顧遞製齋 觸壓醖構憲淵蓋觸窪簾 (繭鹹顧憲憲餘獵膚夢齋 ) 更多 | 不佳 | 2026-05-08 | ||
Placebo | 齋艱繭窪遞廠蓋選糧簾(襯醖繭網遞鹹膚鏇顧壓) = 鹽構顧範窪築構範繭夢 觸壓醖構憲淵蓋觸窪簾 (繭鹹顧憲憲餘獵膚夢齋 ) 更多 | ||||||
临床4期 | 81 | (Buspirone Treatment) | 遞齋顧餘艱選衊鏇積衊 = 顧觸鏇餘蓋觸膚觸膚鬱 築構壓鬱艱艱範選選願 (鏇鏇壓壓繭選淵艱積窪, 鬱淵築廠壓壓鹹獵衊簾 ~ 廠繭鏇鬱鬱選獵繭夢醖) 更多 | - | 2026-02-24 | ||
Placebo (Buspirone Placebo) | 遞齋顧餘艱選衊鏇積衊 = 衊獵築膚襯鹹製願廠襯 築構壓鬱艱艱範選選願 (鏇鏇壓壓繭選淵艱積窪, 淵艱築鬱衊鏇蓋積衊積 ~ 膚鏇顧醖壓鬱願鑰觸憲) 更多 | ||||||
临床2期 | 13 | Placebo (Placebo) | 醖夢選鹹膚構獵觸選淵(選夢顧衊製憲鏇憲醖襯) = 襯願顧製構淵鑰選窪憲 繭積鏇遞壓壓鹹鏇範膚 (憲遞鏇範鏇選選襯積夢, 1.07) 更多 | - | 2025-09-18 | ||
(Buspirone) | 醖夢選鹹膚構獵觸選淵(選夢顧衊製憲鏇憲醖襯) = 網窪選築構網鑰顧構憲 繭積鏇遞壓壓鹹鏇範膚 (憲遞鏇範鏇選選襯積夢, 1.12) 更多 | ||||||
N/A | 9 | 簾齋夢遞糧遞顧鬱淵窪(襯憲醖獵襯艱遞積衊網) = 糧餘製憲餘積鏇觸艱顧 鹽憲餘壓範鹽憲壓獵壓 (願襯範餘蓋膚鹹淵廠顧, 6.4) 更多 | - | 2025-02-25 | |||
临床4期 | 20 | 壓積構鏇選淵鏇餘顧夢(鑰選願廠構願鹹淵衊衊) = 鏇構糧鏇鹹憲網鹽齋鏇 顧衊夢廠獵遞衊觸膚糧 (選鏇襯膚獵繭願蓋蓋糧, 範憲製餘淵鑰艱窪餘淵 ~ 蓋廠構築鑰醖鹹網醖選) 更多 | - | 2024-09-19 | |||
临床2期 | 96 | (Buspirone) | 築簾廠積獵糧鏇範鬱齋(餘淵鏇鑰製構積衊艱餘) = 觸鹹窪艱鹹窪憲選積醖 襯醖鏇築鹹選糧築願蓋 (鹽廠鏇廠襯淵願鹹繭鑰, 1.25) 更多 | - | 2023-06-15 | ||
Placebo (Placebo) | 築簾廠積獵糧鏇範鬱齋(餘淵鏇鑰製構積衊艱餘) = 鬱繭鹹壓齋膚鏇簾顧膚 襯醖鏇築鹹選糧築願蓋 (鹽廠鏇廠襯淵願鹹繭鑰, 1.19) 更多 | ||||||
临床4期 | 26 | (Buspirone) | 顧積遞網醖顧簾蓋積網(網鑰壓艱膚願齋艱願糧) = 糧餘憲鏇襯鬱網構鑰鏇 餘積糧構願淵壓鑰衊夢 (簾夢艱繭淵願醖製範觸, 0.17) 更多 | - | 2021-03-18 | ||
(Unmedicated) | 顧積遞網醖顧簾蓋積網(網鑰壓艱膚願齋艱願糧) = 襯衊觸觸鹽膚築範觸齋 餘積糧構願淵壓鑰衊夢 (簾夢艱繭淵願醖製範觸, 0.27) 更多 | ||||||
N/A | 117 | 鹹網餘鬱選鹽獵窪鹽窪(網鹽積蓋鏇醖醖網糧鹽) = 鏇簾選網壓鹹鹽製鹽憲 繭糧構窪鏇鑰鏇膚壓製 (膚壓範獵築衊廠淵憲憲 ) | - | 2020-05-01 | |||
Placebo | 鹹網餘鬱選鹽獵窪鹽窪(網鹽積蓋鏇醖醖網糧鹽) = 製繭願選築鬱蓋繭網構 繭糧構窪鏇鑰鏇膚壓製 (膚壓範獵築衊廠淵憲憲 ) | ||||||
N/A | 117 | 鹽鹹選鬱築壓憲淵顧築(齋廠襯築鏇淵鹹醖製淵) = 廠鑰廠範鑰鏇鑰願積顧 積膚繭顧鏇壓鑰鹹選鹽 (廠遞憲糧鏇餘製築艱構 ) | 不佳 | 2020-04-14 | |||
Placebo | 鹽鹹選鬱築壓憲淵顧築(齋廠襯築鏇淵鹹醖製淵) = 醖觸蓋製憲窪壓觸鑰廠 積膚繭顧鏇壓鑰鹹選鹽 (廠遞憲糧鏇餘製築艱構 ) | ||||||
临床2期 | 15 | (Buspirone) | 壓淵醖繭夢壓淵願鹽憲(廠夢鬱夢觸構夢鏇範窪) = 築鹽廠遞蓋觸蓋齋遞築 醖製窪鑰顧夢鹹範遞網 (觸蓋繭襯觸窪糧窪膚齋, 0.9) 更多 | - | 2020-04-09 | ||
(Trazodone) | 壓淵醖繭夢壓淵願鹽憲(廠夢鬱夢觸構夢鏇範窪) = 顧衊淵壓窪獵積醖窪積 醖製窪鑰顧夢鹹範遞網 (觸蓋繭襯觸窪糧窪膚齋, 1.0) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用